Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study.
anti-VEGF therapy
panretinal laser photocoagulation
proliferative diabetic retinopathy
ranibizumab
retinal neovascularization
under-treatment
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
08
02
2021
received:
20
08
2020
accepted:
22
04
2021
pubmed:
15
6
2021
medline:
22
2
2022
entrez:
14
6
2021
Statut:
ppublish
Résumé
Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non-interventional follow-up, performed to evaluate long-term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real-life conditions, prior to the approval of ranibizumab for PDR. Seventy-three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow-up phase and treated at the investigators discretion. Visual acuity (VA) measurements and retinal imaging were performed at Months 12, 18 and 24. Mean (± SD) NV area in the ranibizumab monotherapy and combination follow-up groups increased from 3.16 ± 4.30 mm Discontinuation of ranibizumab treatment in PDR patients may result in an increase of NV area and VA loss. Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control.
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e578-e587Subventions
Organisme : Novartis Pharma GmbH
Informations de copyright
© 2021 Novartis Pharma GmbH. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
AAO (2019): AAO Diabetic Retinopathy Preferred Practice Pattern 2019. Retrieved from https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp.
Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487. https://doi.org/10.1056/nejm199412013312203.
Danis RP Davis MD (2008): Proliferative diabetic retinopathy Diabetic Retinopathy. Cham, Switzerland: Springer Nature Switzerland AG, pp. 29-65.
Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft e. V. (RG); Berufsverband der Augenärzte Deutschlands e. V. (BVA): (2020). Supplementary statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on treatment of proliferative diabetic retinopathy: Status November 2019. Ophthalmologe 117: 755-759. https://doi.org/10.1007/s00347-020-01116-3
DRS (1976): Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81: 383-396.
DRS Research Group (1981): Photocoagulation treatment of proliferative diabetic retinopathy DRS Report Number 8. Ophthalmology 88(7): 583-600.
ETDRS RG (1991a): Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98(5 Suppl): 766-785.
ETDRS RG (1991b): Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98(5 Suppl): 786-806.
Figueira J, Silva R, Henriques J, Caldeira Rosa P, Lains I, Melo P, Cunha-Vaz J (2016): Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial. Ophthalmologica 235(1): 34-41. https://doi.org/10.1159/000442026.
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Beck RW (2018): Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol 136(10): 1138-1148. https://doi.org/10.1001/jamaophthalmol.2018.3255.
Kim LA & D'Amore PA (2012): A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 181(2): 376-379. https://doi.org/10.1016/j.ajpath.2012.06.006.
Lang GE, Stahl A, Voegeler J, Quiering C, Lorenz K, Spital G & Liakopoulos S (2020): Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy - the PRIDE study. Acta Ophthalmol 98(5): e530-e539. https://doi.org/10.1111/aos.14312.
Lee R, Wong TY & Sabanayagam C (2015): Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2: 17. https://doi.org/10.1186/s40662-015-0026-2.
Li JQ, Welchowski T, Schmid M, Letow J, Wolpers C, Pascual-Camps I, Finger RP (2020): Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol 35(1): 11-23. https://doi.org/10.1007/s10654-019-00560-z.
Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, Hsu J (2019): Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology 126(3): 407-413. https://doi.org/10.1016/j.ophtha.2018.07.027.
Salam A, Mathew R & Sivaprasad S (2011): Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol 89(5): 405-411.
WHO (2016): Global Report on Diabetes. Retrieved from https://www.who.int/publications/i/item/9789241565257.
Writing Committee for the DRCR, N (2015): Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 314(20): 2137-2146. https://doi.org/10.1001/jama.2015.15217.
Yau JW, Rogers SL, Kawasaki R et al. (2012): Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3): 556-564. https://doi.org/10.2337/dc11-1909.